Founder of 4D Molecular Therapeutics, Inc., Ignite Immunotherapy, Inc. and SillaJen Biotherapeutics, Inc., David H. Kirn currently holds the position of President, Chief Executive Officer & Director at 4D Molecular Therapeutics, Inc.

He is also on the board of Coagulant Therapeutics, Inc. and Professor at the University of Oxford.

In his past career Dr. Kirn was Faculty Member at Specialist Diabetes Research & Treatment Centre LLC, Executive Chairman at Ignite Immunotherapy, Inc., Chief Medical Officer at SillaJen Biotherapeutics, Inc., Vice President-Clinical Research at Onyx Pharmaceuticals, Inc., Principal at Warner-Lambert Co., Advisor at National Institutes of Health, Principal at IP2IPO Innovations Ltd., Member of Harvard University and Faculty Member at The University of California, San Francisco.

Dr. Kirn received a doctorate from The University of California, San Francisco and an undergraduate degree from the University of California, Berkeley.